XBiotech
XBIT
68 hedge funds and large institutions have $75.3M invested in XBiotech in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
28% more capital invested
Capital invested by funds: $58.9M → $75.3M (+$16.4M)
5% more funds holding
Funds holding: 65 → 68 (+3)
1.29% less ownership
Funds ownership: 14.89% → 13.6% (-1.3%)
36% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 28
70% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $3.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.23M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$647K |
| 3 |
VI
Vestcor Inc
Fredericton,
New Brunswick, Canada
|
+$310K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$247K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$226K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.67M |
| 2 |
Jane Street
New York
|
-$1.58M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$993K |
| 4 |
QI
QS Investors
New York
|
-$847K |
| 5 |
CANY
Caxton Associates (New York)
New York
|
-$394K |
XBIT Hedge Fund Activity: Q3 2020 in Review
68 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2020, worth a combined $75.3M — up 28% from $58.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XBIT positions and 6 closed out — a net gain of 3 holders — while 18 added to existing stakes and 28 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.23M. The largest seller was Vanguard Group, cutting an estimated $2.67M.
- 68 institutional investors held XBiotech (XBIT) as of Q3 2020, up from 65 in Q2 2020.
- Funds reported $75.3M of XBiotech stock for Q3 2020, up 28% quarter-over-quarter.
- 9 funds opened new XBiotech positions in Q3 2020 and 6 closed out, a net change of +3 holders.
- The largest XBiotech buyer in Q3 2020 was Northern Trust, an estimated $1.23M added.
- The largest XBiotech seller in Q3 2020 was Vanguard Group, an estimated $2.67M sold.
Based on aggregated 13F filings for Q3 2020.